Free Trial

Qiagen (QGEN) Competitors

$41.86
-0.03 (-0.07%)
(As of 06/21/2024 ET)

QGEN vs. BIIB, ARGX, BNTX, NBIX, TECH, PCVX, RGEN, EXEL, HALO, and RVMD

Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Biogen (BIIB), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.

Qiagen vs.

Qiagen (NYSE:QGEN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.

Biogen has higher revenue and earnings than Qiagen. Biogen is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$1.94B4.93$341.30M$1.4928.09
Biogen$9.84B3.32$1.16B$8.0127.97

Qiagen has a net margin of 17.38% compared to Biogen's net margin of 12.07%. Biogen's return on equity of 14.83% beat Qiagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen17.38% 12.59% 7.67%
Biogen 12.07%14.83%8.19%

Biogen received 1533 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 71.94% of users gave Biogen an outperform vote while only 60.89% of users gave Qiagen an outperform vote.

CompanyUnderperformOutperform
QiagenOutperform Votes
246
60.89%
Underperform Votes
158
39.11%
BiogenOutperform Votes
1779
71.94%
Underperform Votes
694
28.06%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biogen had 10 more articles in the media than Qiagen. MarketBeat recorded 25 mentions for Biogen and 15 mentions for Qiagen. Qiagen's average media sentiment score of 0.52 beat Biogen's score of 0.15 indicating that Qiagen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qiagen
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
9 Very Positive mention(s)
0 Positive mention(s)
15 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Qiagen presently has a consensus target price of $51.17, indicating a potential upside of 22.24%. Biogen has a consensus target price of $286.50, indicating a potential upside of 27.90%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56
Biogen
0 Sell rating(s)
9 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.65

Qiagen has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

Summary

Biogen beats Qiagen on 12 of the 18 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QGEN vs. The Competition

MetricQiagenBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$9.55B$2.87B$5.35B$17.73B
Dividend YieldN/A2.18%2.83%3.62%
P/E Ratio28.0711.54123.7221.89
Price / Sales4.93295.132,167.4014.41
Price / Cash13.42149.7534.2419.18
Price / Book2.513.654.744.82
Net Income$341.30M-$45.13M$110.77M$976.34M
7 Day Performance-1.13%-5.10%-2.23%0.93%
1 Month Performance-3.77%-11.16%-4.45%-3.19%
1 Year Performance-10.60%-7.31%-3.12%8.58%

Qiagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
4.9491 of 5 stars
$223.65
-1.2%
$286.50
+28.1%
-23.9%$32.56B$9.84B27.927,570
ARGX
argenx
2.9653 of 5 stars
$377.96
-0.1%
$520.68
+37.8%
-1.2%$22.46B$1.27B-66.781,148Analyst Revision
BNTX
BioNTech
2.3615 of 5 stars
$86.27
-2.5%
$111.70
+29.5%
-21.2%$20.51B$2.73B172.546,133
NBIX
Neurocrine Biosciences
4.7633 of 5 stars
$130.86
-3.3%
$152.00
+16.2%
+36.5%$13.17B$1.89B36.051,400Analyst Downgrade
TECH
Bio-Techne
4.3654 of 5 stars
$74.54
-0.4%
$81.00
+8.7%
-3.9%$11.75B$1.14B59.163,050Positive News
PCVX
Vaxcyte
0.0902 of 5 stars
$72.25
+0.5%
$78.50
+8.7%
+41.4%$7.86BN/A-16.88254Analyst Forecast
RGEN
Repligen
4.7285 of 5 stars
$123.00
-1.1%
$197.75
+60.8%
-16.1%$6.87B$638.76M492.021,783Analyst Forecast
Positive News
EXEL
Exelixis
4.9723 of 5 stars
$21.56
-1.0%
$26.13
+21.2%
+16.8%$6.54B$1.85B33.691,310Positive News
HALO
Halozyme Therapeutics
4.4069 of 5 stars
$50.27
+1.2%
$54.13
+7.7%
+42.7%$6.40B$829.25M20.77373
RVMD
Revolution Medicines
3.754 of 5 stars
$37.72
+1.7%
$43.20
+14.5%
+48.2%$6.22B$11.58M-10.06378Positive News

Related Companies and Tools

This page (NYSE:QGEN) was last updated on 6/22/2024 by MarketBeat.com Staff

From Our Partners